PCMA
5.6K posts
PCMA
@pcmanet
PCMA is the national association representing America’s pharmacy benefit managers (PBMs). PBMs are working every day to secure savings, enable better health out
Washington, DC Katılım Ocak 2009
1.6K Takip Edilen3.8K Takipçiler
Today, @WaysandMeansGOP is marking up HR 3164, the Ensuring Community Access to Pharmacist Services Act (ECAPS). PCMA supports the legislation’s objective to expand access to care for seniors by allowing Medicare to reimburse pharmacists for important clinical care services they provide to patients.
English
Today, the @EdWorkforceCmte is set to consider the PBM Kickback Prohibition Act, which bars payments from a PBM to a health care broker or consultant.
We welcome this focus and issued the following statement in advance of the markup:
English
Did you know… Pharmacy benefit managers (PBMs) do more than reduce the cost of prescription drugs – by $300 billion each year. PBMs also play an important clinical role.
Disease management programs are just one way that PBMs deliver not just savings, but also services and safety for American families.
English
PCMA retweetledi
Members of Congress are “not fully aware of the massive reforms and transparency [that are] now the law of the land,” @PCMANet president and CEO David Marin told @mayagoldman_ at #AxiosFOH.
“We’re gonna make sure we’re aligned and integrated in telling our stories.”
English
Tune In Now: PCMA President and CEO David Marin speaking at the @Axios Future of Health Summit #AxiosFoH
Axios@axios
WATCH: @axios hosts conversations on the future of U.S. healthcare — from drug pricing to digital health — featuring @DrOzCMS, @SenPeterWelch, @SenatorMarshall, @PhRMA, @bmsnews, @PCMAnet, @CLEAR, @WHOOP, @WW_us & @sesamecare. #AxiosLive x.com/i/broadcasts/1…
English
Wholesalers are one of the most overlooked and most influential players in the drug supply chain.
In her latest piece, PCMA's Amanda Frost, Vice President of Research, outlines key questions that policymakers should be asking about the role wholesalers play and the influence they have.
English
A new @dcexaminer oped argues that a proposed PBM transparency rule from @USDOL is duplicative of CAA reforms and will drive up health care costs.
It's time for the rule to be rescinded.
English
Learn more about how "pay for delay" keeps drug prices high here: pcmanet.org/pcma-blog/pate…
English
For years, big drugmakers have been waging a war against patient access to affordable generic drugs. Their newest ad campaign lays bare its fight to drive patients to costly brand drugs over affordable generics.
We're exposing their strategy - and setting the record straight.
Read more: pcmanet.org/pcma-blog/big-…
English
PCMA endorses @SecKennedy's call for nationwide Real-Time Pharmacy Benefit Technology
Secretary Kennedy@SecKennedy
I’m calling on health IT vendors and providers nationwide to adopt prescription price transparency so Americans never face surprises at the pharmacy counter.
English
@BPC_Bipartisan is the latest organization to call attention to Big Pharma’s patent abuse games.
In a new report, BPC explains several patent abuses drugmakers use to extend barriers to entry for generic drugs and maintain high prices.
Bipartisan Policy Center@BPC_Bipartisan
Biologics and specialty drugs represent some of the most promising advances in health innovation — but they also come with complex pricing dynamics. Biosimilar competition is more complicated than with traditional generics and can face regulatory hurdles. We break down key price drivers affecting costs for patients. 🔗
English
Why are some of the most expensive prescription drugs in Medicare insulated from competition long after their original patents should have expired?
The answer, according to a new report from I-MAK, is Big Pharma’s “Monopoly Extension Menu,” tactics that result in unchecked monopoly power and higher costs for patients.
Initiative for Medicines, Access & Knowledge@IMAKglobal
Pomalyst, Darzalex, and Trelegy Ellipta account for $9.9 billion in annual Medicare spending, ranking among the highest-cost drugs in the program. Why are these drugs so expensive, and why has generic or biosimilar competition failed to materialize? The answer lies in what we call the ‘Monopoly Extension Menu’—a set of overlapping schemes that pharmaceutical companies deploy to exploit the U.S. patent system in order to maintain market exclusivity. reports.i-mak.org/monopoly-exten…
English